Clinical Trials Browser

Triple Negative Breast Neoplasms × veliparib × 1 year × Clear all

NCT01042379 2026-03-13

I-SPY

Phase 2 Recruiting

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT02158507 2026-01-22

Pilot Study of Veliparib (ABT-888) and Lapatinib (Tykerb) in Patients With Metastatic, Triple Negative Breast Cancer

Phase NA Completed

20 enrolled 10 charts

Triple Negative Breast Neoplasms

NCT01251874 2025-11-21

Veliparib and Carboplatin in Treating Patients With HER2-Negative Metastatic Breast Cancer

Phase 1 Active not recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02595905 2025-05-16

Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases

Phase 2 Completed

Brain Neoplasms, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01818063 2025-04-30

Carboplatin and Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IIB-IIIC Breast Cancer

Phase 2 Completed

9 enrolled 10 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT00576654 2025-04-15

Veliparib and Irinotecan Hydrochloride in Treating Patients With Cancer That Is Metastatic or Cannot Be Removed by Surgery

Phase 1 Completed

Neoplasm Metastasis, Triple Negative Breast Neoplasms